TY - JOUR
T1 - Ultrabright plasmonic fluor nanolabel-enabled detection of a urinary ER stress biomarker in autosomal dominant tubulointerstitial kidney disease
AU - Kim, Yeawon
AU - Wang, Zheyu
AU - Li, Chuang
AU - Kidd, Kendrah
AU - Wang, Yixuan
AU - Johnson, Bryce G.
AU - Kmoch, Stanislav
AU - Morrissey, Jeremiah J.
AU - Bleyer, Anthony J.
AU - Duffield, Jeremy S.
AU - Singamaneni, Srikanth
AU - Chen, Ying Maggie
N1 - Funding Information:
S.K. was supported by Project LTAUSA19068 from the Ministry of Education, Youth and Sports of the Czech Republic and NV17-29786A from the Ministry of Health of the Czech Republic. A.J.B. was supported by National Institutes of Health (NIH) Grant R21DK106584. J.M. was supported by NIH Grant R01CA141521. S.S. was supported by National Science Foundation Awards CBET-1908167 and CBET-1900277 and NIH Grant R21CA23665202. Y.M.C. was supported by NIH Grants R01DK105056A1, R03DK106451, and K08DK089015 and the Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program under Award W81XWH-19-1-0320, George M. O'Brien Kidney Research Core Center (NU GoKidney, NIH Grant P30DK114857), a Mallinckrodt challenge grant, Washington University Center for Drug Discovery, Investigator Matching Micro Grant, Faculty Scholar Award (MD-FR-2013-336) from the Children's Discovery Institute of Washington University and St. Louis Children's Hospital, and Career Development Award from the Nephrotic Syndrome Study Network. Y.M.C. is a member of Washington University Institute of Clinical and Translational Sciences (UL1TR000448) and Diabetes Research Center (NIH Grant P30DK020579). We also thank the Slim Health Foundation and Black-Brogan Foundation for support.
Funding Information:
We thank the Musculoskeletal Research Center Morphology Core (supported by National Institutes of Health Grant
Funding Information:
S.K. was supported by Project LTAUSA19068 from the Ministry of Education, Youth and Sports of the Czech Republic and NV17-29786A from the Ministry of Health of the Czech Republic. A.J.B. was supported by National Institutes of Health (NIH) Grant R21DK106584. J.M. was supported by NIH Grant R01CA141521. S.S. was supported by National Science Foundation Awards CBET-1908167 and CBET-1900277 and NIH Grant R21CA23665202. Y.M.C. was supported by NIH Grants R01DK105056A1, R03DK106451, and K08DK089015 and the Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program under Award W81XWH-19-1-0320, George M. O’Brien Kidney Research Core Center (NU GoKidney, NIH Grant P30DK114857), a Mallinckrodt challenge grant, Washington University Center for Drug Discovery, Investigator Matching Micro Grant, Faculty Scholar Award (MD-FR-2013-336) from the Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital, and Career Development Award from the Nephrotic Syndrome Study Network. Y.M.C. is a member of Washington University Institute of Clinical and Translational Sciences (UL1TR000448) and Diabetes Research Center (NIH Grant P30DK020579). We also thank the Slim Health Foundation and Black-Brogan Foundation for support.
Publisher Copyright:
© 2021 the American Physiological Society.
PY - 2021/8
Y1 - 2021/8
N2 - Autosomal dominant tubulointerstitial kidney disease (ADTKD)-uromodulin (UMOD) is the most common nonpolycystic genetic kidney disease, but it remains unrecognized due to its clinical heterogeneity and lack of screening test. Moreover, the fact that the clinical feature is a poor predictor of disease outcome further highlights the need for the development of mechanistic biomarkers in ADTKD. However, low abundant urinary proteins secreted by thick ascending limb cells, where UMOD is synthesized, have posed a challenge for the detection of biomarkers in ADTKD-UMOD. In the CRISPR/Cas9-generated murine model and patients with ADTKD-UMOD, we found that immunoglobulin heavy chain-binding protein (BiP), an endoplasmic reticulum chaperone, was exclusively upregulated by mutant UMOD in the thick ascending limb and easily detected by Western blot analysis in the urine at an early stage of disease. However, even the most sensitive ELISA failed to detect urinary BiP in affected individuals. We therefore developed an ultrasensitive, plasmon-enhanced fluorescence-linked immunosorbent assay (p-FLISA) to quantify urinary BiP concentration by harnessing the newly invented ultrabright fluorescent nanoconstruct, termed “plasmonic Fluor.” p-FLISA demonstrated that urinary BiP excretion was significantly elevated in patients with ADTKD-UMOD compared with unaffected controls, which may have potential utility in risk stratification, disease activity monitoring, disease progression prediction, and guidance of endoplasmic reticulum-targeted therapies in ADTKD. NEW & NOTEWORTHY Autosomal dominant tubulointerstitial kidney disease (ADTKD)-uromodulin (UMOD) is an underdiagnosed cause of chronic kidney disease (CKD). Lack of ultrasensitive bioanalytical tools has hindered the discovery of low abundant urinary biomarkers in ADTKD. Here, we developed an ultrasensitive plasmon-enhanced fluorescence-linked immunosorbent assay (p-FLISA). p-FLISA demonstrated that secreted immunoglobulin heavy chain-binding protein is an early urinary endoplasmic reticulum stress biomarker in ADTKD-UMOD, which will be valuable in monitoring disease progression and the treatment response in ADTKD.
AB - Autosomal dominant tubulointerstitial kidney disease (ADTKD)-uromodulin (UMOD) is the most common nonpolycystic genetic kidney disease, but it remains unrecognized due to its clinical heterogeneity and lack of screening test. Moreover, the fact that the clinical feature is a poor predictor of disease outcome further highlights the need for the development of mechanistic biomarkers in ADTKD. However, low abundant urinary proteins secreted by thick ascending limb cells, where UMOD is synthesized, have posed a challenge for the detection of biomarkers in ADTKD-UMOD. In the CRISPR/Cas9-generated murine model and patients with ADTKD-UMOD, we found that immunoglobulin heavy chain-binding protein (BiP), an endoplasmic reticulum chaperone, was exclusively upregulated by mutant UMOD in the thick ascending limb and easily detected by Western blot analysis in the urine at an early stage of disease. However, even the most sensitive ELISA failed to detect urinary BiP in affected individuals. We therefore developed an ultrasensitive, plasmon-enhanced fluorescence-linked immunosorbent assay (p-FLISA) to quantify urinary BiP concentration by harnessing the newly invented ultrabright fluorescent nanoconstruct, termed “plasmonic Fluor.” p-FLISA demonstrated that urinary BiP excretion was significantly elevated in patients with ADTKD-UMOD compared with unaffected controls, which may have potential utility in risk stratification, disease activity monitoring, disease progression prediction, and guidance of endoplasmic reticulum-targeted therapies in ADTKD. NEW & NOTEWORTHY Autosomal dominant tubulointerstitial kidney disease (ADTKD)-uromodulin (UMOD) is an underdiagnosed cause of chronic kidney disease (CKD). Lack of ultrasensitive bioanalytical tools has hindered the discovery of low abundant urinary biomarkers in ADTKD. Here, we developed an ultrasensitive plasmon-enhanced fluorescence-linked immunosorbent assay (p-FLISA). p-FLISA demonstrated that secreted immunoglobulin heavy chain-binding protein is an early urinary endoplasmic reticulum stress biomarker in ADTKD-UMOD, which will be valuable in monitoring disease progression and the treatment response in ADTKD.
KW - Autosomal dominant tubulointerstitial kidney disease
KW - Biomarker
KW - Endoplasmic reticulum stress
KW - Plasmon-enhanced fluorescence-linked immunosorbent assay
UR - http://www.scopus.com/inward/record.url?scp=85113629862&partnerID=8YFLogxK
U2 - 10.1152/AJPRENAL.00231.2021
DO - 10.1152/AJPRENAL.00231.2021
M3 - Article
C2 - 34251273
AN - SCOPUS:85113629862
SN - 0363-6127
VL - 321
SP - F236-F244
JO - American Journal of Physiology - Renal Physiology
JF - American Journal of Physiology - Renal Physiology
IS - 2
ER -